Navigation Links
Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Date:1/13/2009

PALO ALTO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced completion of enrollment in the second of two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

"Completion of enrollment in this second trial is a meaningful milestone in the JZP-6 program in fibromyalgia. We expect to report top-line results from this trial in mid-2009," said Samuel Saks, M.D., Chief Executive Officer.

The JZP-6 Phase III clinical trial program includes two randomized, double blind, placebo-controlled studies. The first study was completed and positive top-line results were announced in November 2008. The second Phase III study has enrolled 575 patients at centers in the U.S. and Europe.

Jazz Pharmaceuticals anticipates submitting a New Drug Application for sodium oxybate to the U.S. Food and Drug Administration by the end of 2009. UCB has the exclusive marketing and distribution rights to sodium oxybate for fibromyalgia in Europe and many other countries outside North America.

About Sodium Oxybate

Sodium oxybate is the sodium salt form of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of GABA. While the precise mechanism of action is unknown, the effects may be mediated in part through interaction with GABA(B) and GHB receptors. Sodium oxybate is the active ingredient in XYREM(R), approved by the FDA for the treatment of excessive daytime sleepiness (EDS) and cataplexy (the sudden loss of muscle tone) in adult patients with narcolepsy. The American Academy of Sleep Medicine recommends sodium oxybate as a standard of care for the U.S. Food and Drug Administration-approved indications. It is also approved by the European Medical Evaluation Agency (EMEA) for the treatment o
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Research and Markets  has ... Pralmorelin" report to their offering. Global ... data on Pralmorelin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... ANN ARBOR, Mich. and ... a non-profit corporation established to bring cutting-edge next-generation ... trials to cancer patients, today announced a collaboration ... molecular capabilities to characterize patient tissue samples from ... be sensitive or resistant to TESARO,s TSR-011.  This may ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Corp., formerly known as InstaCare Corp., (OTCQB: ISCRD), a ... the chronically ill, a leading fulfillment provider of direct ... revolutionary cell phone centric e -health products and ... Dividend will be Ex-Dividend to all shareholders of record ...
... ENDP ) today announced that David Holveck, president ... Morgan 30th Annual Healthcare Conference on Monday, January 9, 2012 ... the Westin St. Francis in San Francisco, Calif. ... be available on the company,s website at http://www.endo.com/ .  ...
Cached Medicine Technology:Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy 2
(Date:8/21/2014)... 21, 2014 Only 20 percent of healthcare ... Affordable Care Act according to a new report . ... responding to a request from Smart Data pioneer ... lead providers to violate privacy laws in many states. , ... many hospitals and clinics are failing to do so in ...
(Date:8/21/2014)... 21, 2014 Inc. magazine ranked Centurion ... 500|5000, an exclusive ranking of the nation's fastest-growing private ... the most important segment of the economy—America’s independent entrepreneurs. ... LinkedIn, Zillow, and many other well-known names gained early ... is proud to have been named to the Inc. ...
(Date:8/21/2014)... Houston, TX (PRWEB) August 21, 2014 Sometimes you ... destiny. , In his new book “From Zero to a Hundred: ... police officer, shares his story of surviving a broken family, a ... “Adversity brings affirmation of who you were created to be,” Roy ... zero,’ which is why I know my purpose today of helping ...
(Date:8/21/2014)... CQIIP, Continuous Quality Immunization Improvement ... Control and Prevention and the Department of Defense. ... the immunization standards and are administered in accordance ... on Immunizations. , ACC chose to adopt the ... place to protect patients, improve efficiency, and increase ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... aging interventions and addressing the challenges of ... concept, OncoFinder, for signalome-wide pathway analysis. ... robust cross-platform analysis of gene expression data ... research, published in the journal Frontiers in ...
Breaking Medicine News(10 mins):Health News:Report: Only 20 Percent of Healthcare Providers Meet ACA Requirement 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:ACC Health Raises the Bar Again by Completing the CQIIP Certification Program 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... JUPITER, FL, May 28, 2009 Current tests to identify specific ... diseases (such as mad cow) in animals and humans, can ... results a time-lag that may put human populations at ... Research Institute,s Florida campus have developed a new method that ...
... Inc. (NYSE: DVA ) announced today ... the Company,s Board of Directors. (Logo: ... former President of American Express International, Japan, Asia-Pacific, ... the Consumer Card business across 12 countries, heading ...
... Annoying seasonal allergies is now a year round threat. ... to nest in the home. Indoor air pollution is ... chemicals, synthetic materials and impurities. To expel these year ... to home ventilation and eliminates allergens.The EZ Breathe system ...
... The best respiratory protection is useless if it ... series, Draeger dedicated special attention to ensuring that the ... comfort of the wearer was maximized. While offering extremely ... been compromised. (Photo: http://www.newscom.com/cgi-bin/prnh/20090528/NE24067 ...
... Darwin National,Assurance Company, a member company of Allied ... ), today announced that Becky Cox has been ... Ms. Cox will,be responsible for the continued development ... Fred Bautista, Vice,President, Business Development, Healthcare. , ...
... of overdose, and potential liver damage, is still too ... -- One month after mandating stricter warning labels about ... U.S. regulators are contemplating even tougher standards. , Advisers ... late next month to review a new agency report ...
Cached Medicine News:Health News:Scripps Florida scientists devise accelerated method to determine infectious prion strains 2Health News:Scripps Florida scientists devise accelerated method to determine infectious prion strains 3Health News:Pamela M. Arway Joins DaVita Board of Directors 2Health News:EZ Breathe(R) Home Ventilation System Expels Allergens, Moisture and Smells 2Health News:Comfort Matters - The new Draeger Series of Filtering Facepiece Respirators Demonstrate Exceptional Wearer Comfort 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 3Health News:FDA Report Urges Tougher Acetaminophen Warning 2
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... Aplicare's disposable 1-ounce pouches are designed for ... waste. They are used in nursing homes, ... rooms and many other hospital departments. This ... is a mild antiseptic, germicidal and cleansing ...
... Aplicare's Iodine Scrub is a gentle ... formulated to prevent dryness. Povidone Iodine is ... gram-negative and gram-positive bacteria, fungi, viruses, protozoa ... lather; the first step in patient pre-operative ...
... Iodine Scrub is a gentle and effective ... prevent dryness. Povidone Iodine is known to ... gram-positive bacteria, fungi, viruses, protozoa and yeasts. ... first step in patient pre-operative prepping, as ...
Medicine Products: